|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Small W Jr, Bacon MA, Bajaj A, Chuang LT,
Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR,
Viswanathan AN and Gaffney DK: Cervical cancer: A global health
crisis. Cancer. 123:2404–2412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen PA, Jhingran A, Oaknin A and Denny
L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lim AW, Ramirez AJ, Hamilton W, Sasieni P,
Patnick J and Forbes LJ: Delays in diagnosis of young females with
symptomatic cervical cancer in England: An interview-based study.
Br J Gen Pract. 64:e602–e610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tewari KS, Sill MW, Long HJ III, Penson
RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao
MM, et al: Improved survival with bevacizumab in advanced cervical
cancer. N Engl J Med. 370:734–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minion LE and Tewari KS: Cervical
cancer-state of the science: From angiogenesis blockade to
checkpoint inhibition. Gynecol Oncol. 148:609–621. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Viallard C and Larrivée B: Tumor
angiogenesis and vascular normalization: Alternative therapeutic
targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Majidpoor J and Mortezaee K: Angiogenesis
as a hallmark of solid tumors-clinical perspectives. Cell Oncol
(Dordr). 44:715–737. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iakovlev VV, Gabril M, Dubinski W,
Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S,
Arsanious A, et al: Microvascular density as an independent
predictor of clinical outcome in renal cell carcinoma: An automated
image analysis study. Lab Invest. 92:46–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bais C, Mueller B, Brady MF, Mannel RS,
Burger RA, Wei W, Marien KM, Kockx MM, Husain A and Birrer MJ; NRG
Oncology/Gynecologic Oncology Group, : Tumor microvessel density as
a potential predictive marker for bevacizumab benefit: GOG-0218
biomarker analyses. J Natl Cancer Inst. 109:djx0662017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuan Y, Min SJ, Xu DQ, Shen Y, Yan HY,
Wang Y, Wang W and Tan YJ: Expressions of VEGF and miR-21 in tumor
tissues of cervical cancer patients with HPV infection and their
relationships with prognosis. Eur Rev Med Pharmacol Sci.
22:6274–6279. 2018.PubMed/NCBI
|
|
12
|
Hu X, Liu H, Ye M and Zhu X: Prognostic
value of microvessel density in cervical cancer. Cancer Cell Int.
18:1522018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nicolussi A, D'Inzeo S, Capalbo C,
Giannini G and Coppa A: The role of peroxiredoxins in cancer. Mol
Clin Oncol. 6:139–153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim Y and Jang HH: The role of
peroxiredoxin family in cancer signaling. J Cancer Prev. 24:65–71.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S,
Yoon K, Jung M and Choe W: Expression of human peroxiredoxin
isoforms in response to cervical carcinogenesis. Oncol Rep.
21:1391–1396. 2009.PubMed/NCBI
|
|
16
|
Zhu H, Tao X, Zhou L, Sheng B and Zhu X
and Zhu X: Expression of thioredoxin 1 and peroxiredoxins in
squamous cervical carcinoma and its predictive role in NACT. BMC
Cancer. 19:8652019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang DH, Lee DJ, Lee KW, Park YS, Lee JY,
Lee SH, Koh YJ, Koh GY, Choi C, Yu DY, et al: Peroxiredoxin II is
an essential antioxidant enzyme that prevents the oxidative
inactivation of VEGF receptor-2 in vascular endothelial cells. Mol
Cell. 44:545–558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
International Agency for Research on
Cancer (IARC), . WHO classification of tumours editorial board: WHO
classification of female genital tumour. 5th edition. IARC; Lyon:
2020
|
|
19
|
Salvo G, Odetto D, Pareja R, Frumovitz M
and Ramirez PT: Revised 2018 international federation of gynecology
and obstetrics (FIGO) cervical cancer staging: A review of gaps and
questions that remain. Int J Gynecol Cancer. 30:873–878. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li S, Hu X, Ye M and Zhu X: The prognostic
values of the peroxiredoxins family in ovarian cancer. Biosci Rep.
38:BSR201806672018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Y, Wang P, Hu W and Chen D: New
insights into the roles of peroxiredoxins in cancer. Biomed
Pharmacother. 164:1148962023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee DJ, Kang DH, Choi M, Choi YJ, Lee JY,
Park JH, Park YJ, Lee KW and Kang SW: Peroxiredoxin-2 represses
melanoma metastasis by increasing E-Cadherin/β-Catenin complexes in
adherens junctions. Cancer Res. 73:4744–4757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Zhao Y, Luo W, Chen S, Lin F,
Zhang X, Fan S, Shen X, Wang Y and Liang G: Celastrol induces
ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in
gastric cancer cells. Theranostics. 10:10290–10308. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi J, Zhou L, Huang HS, Peng L, Xie N,
Nice E, Fu L, Jiang C and Huang C: Repurposing oxiconazole against
colorectal cancer via PRDX2-mediated autophagy arrest. Int J Biol
Sci. 18:3747–3761. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung AS, Lee J and Ferrara N: Ferrara.
targeting the tumour vasculature: Insights from physiological
angiogenesis. Nat Rev Cancer. 10:505–514. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abid MR, Spokes KC, Shih SC and Aird WC:
NADPH oxidase activity selectively modulates vascular endothelial
growth factor signaling pathways. J Biol Chem. 282:35373–35385.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang S, Fu Z, Wei J, Guo J, Liu M and Du
K: Peroxiredoxin 2 is involved in vasculogenic mimicry formation by
targeting VEGFR2 activation in colorectal cancer. Med Oncol.
32:4142015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vieira SC, Silva BB, Pinto GA, Vassallo J,
Moraes NG, Santana JO, Santos LG, Carvasan GA and Zeferino LC: CD34
as a marker for evaluating angiogenesis in cervical cancer. Pathol
Res Pract. 201:313–318. 2005. View Article : Google Scholar : PubMed/NCBI
|
